The latest announcement is out from AstraZeneca ( (GB:AZN) ).
AstraZeneca’s Calquence, in combination with bendamustine and rituximab, has been recommended for approval by the CHMP in the EU for first-line treatment of mantle cell lymphoma (MCL), marking it as the first BTK inhibitor for this indication. The recommendation is based on the ECHO Phase III trial results, which showed a significant improvement in progression-free survival, potentially transforming the standard of care for MCL patients in Europe.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.
YTD Price Performance: 10.64%
Average Trading Volume: 2,777,481
Technical Sentiment Signal: Strong Sell
Current Market Cap: £177B
For detailed information about AZN stock, go to TipRanks’ Stock Analysis page.